<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980849</url>
  </required_header>
  <id_info>
    <org_study_id>LCAN-20131105</org_study_id>
    <nct_id>NCT01980849</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer</brief_title>
  <acronym>LCAN</acronym>
  <official_title>Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengqing Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin
      during hospitalization to long-term usage in patients with advanced lung cancer treated by
      chemotherapy and/or radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized and controlled study. Advanced lung cancer
      patients without venous thromboembolism(VTE) are included. The selected patients were
      randomized into A and B groups. Group A: Nadroparin given during hospitalization, 0.4mL,
      subcutaneously, qid; Group B: Nadroparin given by long-term, 0.4mL, subcutaneously, qid. The
      incidence of VTE , the risks of bleeding and overall survival in two groups of patients are
      studied at different time points.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of venous thromboembolism</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding</measure>
    <time_frame>During 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Long term prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nadroparin, 0.4mL, subcutaneously, qid, given by long-term</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short-term prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin, long term</intervention_name>
    <arm_group_label>Long term prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin: short-term</intervention_name>
    <arm_group_label>Short-term prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage Ⅲ B and Ⅳ non-small cell lung cancer patients and inoperable small cell lung
             cancer patients

          -  Performance status score ≤ 2

          -  Chest CT with measurable lesions

        Exclusion Criteria:

          -  Examination revealed any part of venous thromboembolism

          -  Chemotherapy regimens containing bevacizumab or Endostar

          -  Severe coagulopathy

          -  Active bleeding within two weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shengqing Li, MD, PhD</last_name>
    <phone>+86-29-84771132</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The Department of Oncology，Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihua Ruan, MD</last_name>
      <phone>13883933815</phone>
      <email>rzh1234@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhihua Ruan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine,Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Xiong, MD</last_name>
      <phone>13512345225</phone>
      <email>xiongwei64@126.com</email>
    </contact>
    <investigator>
      <last_name>Wei Xiong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Ohtsubo Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqin Yang, MD</last_name>
      <phone>15923366936</phone>
      <email>yxq92@163.com</email>
    </contact>
    <investigator>
      <last_name>Xueqin Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Fuling Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>408000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou, MD</last_name>
      <phone>18996706515</phone>
      <email>qizhou112@163.com</email>
    </contact>
    <investigator>
      <last_name>Qi Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Central Hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guifang Zhang, MD</last_name>
      <phone>15637359110</phone>
      <email>xxchzhangguifang@126.com</email>
    </contact>
    <investigator>
      <last_name>Guifang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhifen Luo, MD</last_name>
      <phone>13783526222</phone>
      <email>luozhifen123@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhifen Luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine,Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqiu Zhao, MD</last_name>
      <phone>13938252350</phone>
      <email>13938252350@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanqiu Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Henan University Affiliated Yihe Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450047</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanwei Guo, MD</last_name>
      <phone>15238608788</phone>
      <email>zzymyygyw@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanwei Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Cancer Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Li, MD</last_name>
      <phone>13847293318</phone>
      <email>2469931063@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jie Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Northern Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>150200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengyun Wang, MD</last_name>
      <phone>15047243095</phone>
      <email>wfy2826@163.com</email>
    </contact>
    <investigator>
      <last_name>Fengyun Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Inner Mongolia Autonomous Region Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuiying Zhang, MD</last_name>
      <phone>13947119586</phone>
      <email>cenyao_2006@126.com</email>
    </contact>
    <investigator>
      <last_name>Cuiying Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine,Medical University General Hospital cardiovascular and cerebrovascular disease hospital</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Yin, MD</last_name>
      <phone>13014292909</phone>
      <email>dmeiyin@163.com</email>
    </contact>
    <investigator>
      <last_name>Mei Yin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine,Central Hospital</name>
      <address>
        <city>Baoji</city>
        <state>Shaanxi</state>
        <zip>721008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengxia Wu, MD</last_name>
      <phone>13891731289</phone>
      <email>Wzx1289@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhengxia Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine,Second People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhangqin Chen, MD</last_name>
      <phone>18991211556</phone>
      <email>1191846052@qq.com</email>
    </contact>
    <investigator>
      <last_name>Zhangqin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manxiang Li, MD, PhD</last_name>
      <phone>15129312682</phone>
      <email>Manxiangli@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Manxiang Li, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine, Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonghong Xie, MD, PhD</last_name>
      <phone>+86-29-84777725</phone>
      <email>xieyh65@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yonghong Xie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine, Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuemin Yang, MD</last_name>
      <phone>+86-29-84775237</phone>
      <email>yangxuemin0622@163.com</email>
    </contact>
    <investigator>
      <last_name>Xuemin Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，First Affiliated Hospital of Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yao, MD</last_name>
      <phone>13572101611</phone>
      <email>13572101611@163.com</email>
    </contact>
    <investigator>
      <last_name>Yu Yao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Yan'an University Hospital</name>
      <address>
        <city>Yan'an</city>
        <state>Shaanxi</state>
        <zip>716000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Zhao, MD</last_name>
      <phone>18809111001</phone>
      <email>YDFYzhaohon@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Song, MD</last_name>
      <phone>13803436909</phone>
      <email>songxiangeryuan@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiang Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Lung oncology，Tumor Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Yu, MD</last_name>
      <phone>13881864070</phone>
      <email>yuping862@126.com</email>
    </contact>
    <investigator>
      <last_name>Ping Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haitao Lan, MD</last_name>
      <phone>18981838376</phone>
      <email>lanht@sina.com</email>
    </contact>
    <investigator>
      <last_name>Haitao Lan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Oncology，First Affiliated Hospital of Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiming Reheman, MD</last_name>
      <phone>15909002857</phone>
      <email>42113739@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yiming Reheman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Department of Pulmonary and Critical Care Medicine,First Affiliated Hospital of Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kegang Jiao, MD</last_name>
      <phone>13999828305</phone>
      <email>kateone@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Kegang Jiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Consultant, Associate professor</investigator_title>
  </responsible_party>
  <keyword>Nadroparin</keyword>
  <keyword>venous thromboembolism prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

